Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model

por Xue, Hui, Wang, Yuzhuo, MacCormack, Tyson J., Lutes, Tyler, Rice, Christopher, Davey, Michelle, Dugourd, Dominique, Ilenchuk, T. Toney, Stewart, John M.
Publicado 2018

First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors

por Fu, S., Hirte, H., Welch, S., Ilenchuk, T. T., Lutes, T., Rice, C., Fields, N., Nemet, A., Dugourd, D., Piha-Paul, S., Subbiah, V., Liu, L., Gong, J., Hong, D., Stewart, J. M.
Publicado 2017

Erratum to: First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors

por Fu, S., Hirte, H., Welch, S., Ilenchuk, T. T., Lutes, T., Rice, C., Fields, N., Nemet, A., Dugourd, D., Piha-Paul, S., Subbiah, V., Liu, L., Gong, J., Hong, D., Stewart, J. M.
Publicado 2017

In Vivo Detection of Human TRPV6-Rich Tumors with Anti-Cancer Peptides Derived from Soricidin

por Bowen, Chris V., DeBay, Drew, Ewart, H. Stephen, Gallant, Pamela, Gormley, Sean, Ilenchuk, T. Toney, Iqbal, Umar, Lutes, Tyler, Martina, Marzia, Mealing, Geoffrey, Merkley, Nadine, Sperker, Sandra, Moreno, Maria J., Rice, Christopher, Syvitski, Raymond T., Stewart, John M.
Publicado 2013